Nano-X Imaging Ltd.
NASDAQ:NNOXMedical - Devices
-$0.03 today
- Market cap
- $50.94M
- Beta
- 1.17
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.12
Volume 0.52M
Average 1.46M
NNOX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nano-X Imaging Ltd.NASDAQ: NNOX
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development declines year over year
Q4 FY2025 research & development of $4.84M fell 10.4% year over year, behind the -4.7% change in trailing-twelve-month research & development. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Research & development amounted to 147.7% of revenue in FY2025, down 31.1 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.4% toward the trailing-twelve-month pace of -4.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.24M USD
- Year-over-year change
- -4.7%
- 4-year CAGR
- +3.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.24M | -4.7% |
| FY2024 | 2024-12-31 | 20.18M | -22.5% |
| FY2023 | 2023-12-31 | 26.05M | -1.7% |
| FY2022 | 2022-12-31 | 26.51M | +54.8% |
| FY2021 | 2021-12-31 | 17.12M | — |
Research & Development vs competitors
How NNOX compares with its peers on the latest reported figures
- NNOX's LTM Dec 2025 research & development of $19.24M is the 7th highest of the 11 companies compared; the peer median is $20.8M.
- Its year-over-year change of -4.7% is the 7th highest of 11, against a peer median of -2.5%.
- Research & development amounts to 147.7% of revenue for NNOX, versus a peer median of 24.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.68M | +76.6% | +218.7% | 13864.6% | |
| LTM Mar 2026 | $44.26M | -24.0% | -13.0% | 14.6% | |
| LTM Mar 2026 | $33.21M | -3.4% | +10.2% | 22.9% | |
| LTM Mar 2026 | $21.34M | -31.8% | -24.3% | 18.1% | |
| LTM Mar 2026 | $21.15M | -1.0% | +12.6% | 112.1% | |
| LTM Mar 2026 | $20.46M | +7.3% | -4.0% | 5.8% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $18.78M | -12.5% | +2.2% | 58.2% | |
| LTM Mar 2026 | $14.89M | -1.7% | -11.2% | 33.2% | |
| LTM Mar 2026 | $2.57M | -32.8% | -6.3% | 26.8% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding NNOX) | $20.8M | -2.5% | -0.9% | 24.8% | |
Competitors are the stored peer set for NNOX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.3M | 8.58M | 9.91M | 11.28M | 13.02M |
| Cost of Revenue | 2.82M | 15.46M | 16.5M | 21.89M | 25.81M |
| Gross Profit | (1.51M) | (6.88M) | (6.59M) | (10.61M) | (12.79M) |
| Gross Margin | -116.0% | -80.2% | -66.6% | -94.0% | -98.2% |
| Research & Development | 17.12M | 26.51M | 26.05M | 20.18M | 19.24M |
| Selling, General & Admin | 41.74M | 45.63M | 28.39M | 25.75M | 27.1M |
| Operating Expenses | 60.05M | 72.33M | 56M | 46.14M | 47.91M |
| Depreciation & Amortization | 2.29M | 11.51M | 11.81M | 11.73M | 11.7M |
| EBITDA | (59.27M) | (75.7M) | (47.69M) | (45.01M) | (49M) |
| EBITDA Margin | -4544.9% | -882.4% | -481.5% | -398.9% | -376.3% |
| Operating Income | (61.56M) | (109.71M) | (62.59M) | (56.75M) | (60.7M) |
| Operating Margin | -4720.7% | -1279.0% | -631.9% | -502.9% | -466.2% |
| Interest Income | 0 | 789K | 1.65M | 2.87M | 1.42M |
| Interest Expense | 288K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (288K) | (14.67M) | 1.47M | 2.87M | (16.11M) |
| Income Before Tax | (61.85M) | (108.92M) | (61.12M) | (53.87M) | (76.81M) |
| Pre-Tax Margin | -4742.8% | -1269.8% | -617.0% | -477.5% | -589.9% |
| Income Tax Expense | (48K) | (3.68M) | (339K) | (358K) | (1.79M) |
| Net Income | (61.8M) | (105.24M) | (60.78M) | (53.52M) | (75.02M) |
| Net Margin | -4739.1% | -1226.9% | -613.6% | -474.3% | -576.1% |
| EPS (Basic) | (1.28) | (2.01) | (1.08) | (0.91) | (1.16) |
| EPS (Diluted) | (1.28) | (2.01) | (1.08) | (0.91) | (1.16) |
| Weighted Avg Shares | 48.22M | 52.24M | 56.37M | 58.62M | 64.79M |
| Weighted Avg Shares (Diluted) | 48.22M | 52.24M | 56.37M | 58.62M | 64.79M |
Nano-X Imaging Ltd.
NASDAQ:NNOX
Intrinsic Alpha fair value
Locked
Current Price
$0.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.